[{"id":41523,"versionId":16558,"title":"March 2024","type":2,"subType":null,"childSubType":"","date":"3/25/2024","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-march-2024-bcbs.png","url":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/mpu-march-2024-bcbs.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Established for Lifileucel (Amtagvi)\u003c/li\u003e\n\u003cli\u003eReminder: Laboratory Management Coverage Guideline Update\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":41427,"versionId":16558,"title":"February 2024","type":2,"subType":null,"childSubType":"","date":"2/26/2024","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-february-2024-bcbs.png","url":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/mpu-february-2024-bcbs.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eUpdate: Policy Criteria Established (NY only)\u003c/li\u003e\n\u003cli\u003eCriteria for Septoplasty\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":41334,"versionId":16558,"title":"January 2024","type":2,"subType":null,"childSubType":"","date":"1/29/2024","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-january-2024-bcbs.png","url":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/mpu-january-2024-bcbs.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Established for Natalizumab-sztn (Tyruko)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Established for Bevacizumab-tnjn (Avzivi)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Established for Efbemalenograstim alfa-vuxw (Ryzneuta)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Established for ADAMTS13, recombinant-krhn (Adzynma)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Established for Exagamglogene autotemcel (Casgevy)\u003c/li\u003e\n\u003cli\u003eAnd more \u0026hellip;\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":40554,"versionId":16558,"title":"December 2023","type":2,"subType":null,"childSubType":"","date":"12/22/2023","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbs/NewsletterNotices/MPU/2xbcbs-mpu-dec-2023.png","url":"https://content.highmarkprc.com/Files/Region/hbcbs/NewsletterNotices/MPU/bcbs-mpu-dec-2023.pdf","baseUrl":null,"urlText":"Read","description":"\u003cp\u003eRevised Criteria for Septoplasty\u003c/p\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":40457,"versionId":16558,"title":"November 2023","type":2,"subType":null,"childSubType":"","date":"11/27/2023","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-november-2023-bcbs.png","url":"https://content.highmarkprc.com/Files/NewsletterNotices/MPU/mpu-november-2023-bcbs.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Established for DaxiotulinumtoxinA-lanm (Daxxify)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Established for Actemra Biosimilar\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Bevacizumab-adcd (Vegzelma)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Established for Eflapegrastim-xnst (Rolvedon)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Toripalimab-tpzi (Loqtorzi)\u003c/li\u003e\n\u003cli\u003eAnd more ...\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":40368,"versionId":16558,"title":"October 30, 2023","type":2,"subType":null,"childSubType":"","date":"10/30/2023","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xwny-mpu-october-2023-103023.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/wny-mpu-october-2023-103023.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eBiosimilar Preferred Products Revised for Rituximab\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Established for Eylea HD\u003csup\u003e\u0026reg;\u003c/sup\u003e and Izervay\u003csup\u003eTM\u003c/sup\u003e\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Established for Pozelimab-bbfg (Veopoz)\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Delandistrogene Moxeparvovec (Elevidys)\u003c/li\u003e\n\u003cli\u003eAnd more ...\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":40318,"versionId":16558,"title":"October 2, 2023","type":2,"subType":null,"childSubType":"","date":"10/2/2023","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xwny-mpu-october-2023-100223.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/wny-mpu-october-2023-100223.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eUpdate: Policy Criteria Established\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":40292,"versionId":16558,"title":"September 2023","type":2,"subType":null,"childSubType":"","date":"9/25/2023","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xwny-mpu-september-2023.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/wny-mpu-september-2023.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Established for Donislecel-jujn (Lantidra)\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":39571,"versionId":16558,"title":"August 2023","type":2,"subType":null,"childSubType":"","date":"8/28/2023","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xwny-mpu-august-2023.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/wny-mpu-august-2023.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Established for (Somatrogon-ghla) Ngenla\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Established for Epcoritamab-bysp (Epkinly)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Established for Glofitamab-gxbm (Columvi)\u003c/li\u003e\n\u003cli\u003eReminder: Radiation Oncology Coverage Guideline Update\u003c/li\u003e\n\u003cli\u003eAnd more ...\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":39511,"versionId":16558,"title":"July 2023","type":2,"subType":null,"childSubType":"","date":"7/31/2023","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xwny-mpu-july-2023.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/wny-mpu-july-2023.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003ePolicy Established for Risankizumab-rzaa (Skyrizi\u003csup\u003e\u0026reg;\u003c/sup\u003e)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Established for Efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo)\u003c/li\u003e\n\u003cli\u003eDiagnosis and Treatment of Obstructive Sleep Apnea in Adults\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":39406,"versionId":16558,"title":"June 2023","type":2,"subType":null,"childSubType":"","date":"6/26/2023","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xwny-mpu-june-2023.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/wny-mpu-june-2023.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003ePolicy Established for Tofersen (Qalsody)\u003c/li\u003e\n\u003cli\u003ePolicy Established for Delandistrogene moxeparvovec\u003c/li\u003e\n\u003cli\u003eNew Guidelines for Assisted Reproductive Technology\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":39344,"versionId":16558,"title":"May 2023","type":2,"subType":null,"childSubType":"","date":"5/26/2023","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xwny-mpu-may-2023.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/wny-mpu-may-2023.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eReminder: Cardiology \u0026amp; Radiology Coverage Guideline Update\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Altuviiio\u003csup\u003e\u003cspan\u003eTM\u003c/span\u003e\u003c/sup\u003e\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Syfovre\u003c/li\u003e\n\u003cli\u003eCriteria for surgical fundoplication added to Medical Policy S-145 Transesophageal Endoscopic Therapies for Gastroesophageal Reflux Disease\u003c/li\u003e\n\u003cli\u003eAnd more ...\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":39258,"versionId":16558,"title":"April 2023","type":2,"subType":null,"childSubType":"","date":"4/24/2023","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xwny-mpu-april-2023.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/wny-mpu-april-2023.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eReminder: Laboratory Management Coverage Guideline Update\u003c/li\u003e\n\u003cli\u003eReminder: Musculoskeletal Coverage Guideline Update\u003c/li\u003e\n\u003cli\u003eGuidelines Revised for Intravenous Anesthetics for Off-Label Indications\u003c/li\u003e\n\u003cli\u003eInjectable Drugs Added to Site of Care\u003c/li\u003e\n\u003cli\u003eAnd more ...\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":39168,"versionId":16558,"title":"March 2023","type":2,"subType":null,"childSubType":"","date":"3/27/2023","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xwny-mpu-march-2023.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/wny-mpu-march-2023.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003ePolicy Criteria Revised for Sutimlimab-jome (Enjaymo)\u003c/li\u003e\n\u003cli\u003ePolicy Established for Teplizumab-mzwv (Tzield)\u003c/li\u003e\n\u003cli\u003ePolicy Established for Nadofaragene firadenovec-vncg (Adstiladrin)\u003c/li\u003e\n\u003cli\u003ePolicy Established for Mosunetuzumab-axgb (Lunsumio)\u003c/li\u003e\n\u003cli\u003ePolicy Established for Ublituximab-xiiy (Briumvi)\u003c/li\u003e\n\u003cli\u003eReminder: Musculoskeletal Coverage Guideline Update\u003c/li\u003e\n\u003cli\u003eAnd more ...\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":38293,"versionId":16558,"title":"January 2023","type":2,"subType":null,"childSubType":"","date":"1/30/2023","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xwny-mpu-january-2023.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/wny-mpu-january-2023.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eHepatobiliary System Imaging\u003c/li\u003e\n\u003cli\u003eAnd more...\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":37963,"versionId":16558,"title":"December 2022","type":2,"subType":null,"childSubType":"","date":"12/22/2022","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xmpu-wny-december-2022.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/mpu-wny-december-2022.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCriteria Revision for Obesity\u003c/li\u003e\n\u003cli\u003ePolicy Established for Tremelimumab (Imjudo)\u003c/li\u003e\n\u003cli\u003ePolicy Established for Teclistamab-cqyv (Tecvayli)\u003c/li\u003e\n\u003cli\u003eReminder: Radiology/Cardiology Coverage Guideline Update\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":37845,"versionId":16558,"title":"November 2022","type":2,"subType":null,"childSubType":"","date":"11/28/2022","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xmpu-wny-november-2022.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/mpu-wny-november-2022.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Established for Bevacizumab-adcd (Vegzelma)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Established for Eflapegrastim-xnst (Rolvedon)\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":37707,"versionId":16558,"title":"October 2022","type":2,"subType":null,"childSubType":"","date":"10/31/2022","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xmpu-wny-october-2022.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/mpu-wny-october-2022.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eReminder: Laboratory Management Coverage Guideline Update\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Pegfilgrastim-pbbk (Fylnetra\u003csup\u003e\u0026reg;\u003c/sup\u003e)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Established for ranibizumab-eqrn (Cimerli)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Betibeglogene autotemcel (Zynteglo)\u003c/li\u003e\n\u003cli\u003eInjectable Drug Added to Site of Care\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":37592,"versionId":16558,"title":"September 2022","type":2,"subType":null,"childSubType":"","date":"9/26/2022","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xmpu-wny-september-2022.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/mpu-wny-september-2022.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Established for Leuprolide Mesylate (Camcevi\u003csup\u003eTM\u003c/sup\u003e)\u003c/li\u003e\n\u003cli\u003eBiosimilar Preferred Products Established for Filgrastim\u003c/li\u003e\n\u003cli\u003ePolicy Established for Risankizumab-rzaa (Skyrizi\u003csup\u003e\u0026reg;\u003c/sup\u003e)\u003c/li\u003e\n\u003cli\u003eReauthorization Criteria Established for Crizanlizumab-tmca (Adakveo)\u003c/li\u003e\n\u003cli\u003eDiagnosis Codes Revised for Medical Policy Z-1, Ultraviolet Light Therapies\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":37510,"versionId":16558,"title":"August 2022","type":2,"subType":null,"childSubType":"","date":"8/29/2022","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xmpu-wny-august-2022.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/mpu-wny-august-2022.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Omalizumab (Xolair)\u003c/li\u003e\n\u003cli\u003eCriteria Established for Dexamethasone Punctum Insert (Dextenza)\u003c/li\u003e\n\u003cli\u003eCriteria revised for Medical Policy M-13, Intraoperative Neurophysiologic Monitoring\u003c/li\u003e\n\u003cli\u003eObstructive Sleep Apnea Publication Delayed\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":37415,"versionId":16558,"title":"July 2022","type":2,"subType":null,"childSubType":"","date":"7/25/2022","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xmpu-wny-july-2022.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/mpu-wny-july-2022.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Belimumab (Benlysta)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Abatacept (Orencia)\u003c/li\u003e\n\u003cli\u003eCriteria Established for Vutrisiran (Amvuttra)\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Intraepidermal Nerve Fiber Density Testing\u003c/li\u003e\n\u003cli\u003eCriteria Revision for Electrical Nerve Stimulation\u003c/li\u003e\n\u003cli\u003eCriteria Revision for Deep Brain Stimulation\u003c/li\u003e\n\u003cli\u003eAnd more ...\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":36715,"versionId":16558,"title":"June 2022","type":2,"subType":null,"childSubType":"","date":"6/24/2022","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xmpu-wny-june-2022.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/mpu-wny-june-2022.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eInjectable Drug Added to Site of Care\u003c/li\u003e\n\u003cli\u003eREMINDER: Spine Surgery Coverage Guideline Update\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":36690,"versionId":16558,"title":"May 2022","type":2,"subType":null,"childSubType":"","date":"5/27/2022","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xmpu-wny-may-2022.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/mpu-wny-may-2022.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eUpdated Criteria for Wearable Cardioverter-Defibrillator\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Bevacizumab-maly (Alymsys)\u003c/li\u003e\n\u003cli\u003ePolicy Established for Nivolumab and Relatlimab-rmbw (Opdualag)\u003c/li\u003e\n\u003cli\u003ePolicy Established for Asparaginase Erwinia Chrysanthemi (Rylaze)\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Posterior Tibial Nerve Stimulation\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Diagnosis and Treatment of Obstructive Sleep Apnea for Adults\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Diagnosis and Treatment of Obstructive Sleep Apnea in Pediatric Individuals\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":36621,"versionId":16558,"title":"April 2022","type":2,"subType":null,"childSubType":"","date":"4/25/2022","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xmpu-wny-april-2022.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/mpu-wny-april-2022.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eUpdate: Cardiology Coverage Guideline Updated\u003c/li\u003e\n\u003cli\u003eReminder: Musculoskeletal Coverage Guideline Update\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Discography\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":36534,"versionId":16558,"title":"March 2022","type":2,"subType":null,"childSubType":"","date":"3/28/2022","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xmpu-wny-march-2022.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/mpu-wny-march-2022.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eReminder: Laboratory Management Coverage Guideline Update\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Intra-Articular Hyaluronan Injections for Osteoarthritis of the Knee\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Pharmacologic Treatment of Pulmonary Arterial Hypertension\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Pegloticase (Krystexxa)\u003c/li\u003e\n\u003cli\u003eCriteria Established for ranibizumab (Susvimo), ranibizumab-nuna (Byooviz), and faricimab-svoa (Vabysmo)\u003c/li\u003e\n\u003cli\u003eAnd more...\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":36484,"versionId":16558,"title":"February 2022","type":2,"subType":null,"childSubType":"","date":"2/28/2022","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xwny-mpu-feb-2022.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/wny-mpu-feb-2022.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eReminder: Radiation Oncology Coverage Guideline Update\u003c/li\u003e\n\u003cli\u003ePolicy Criteria Established for Tezepelumab-ekko\u003c/li\u003e\n\u003cli\u003ePolicy Established for Tisotumab vendotin-tftv (Tivdak)\u003c/li\u003e\n\u003cli\u003ePolicy Established for Efgartigmod alfa-fcab (Vyvgart)\u003c/li\u003e\n\u003cli\u003eCriteria Revision for Prophylactic Mastectomy\u003c/li\u003e\n\u003cli\u003eAnd more...\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":36385,"versionId":16558,"title":"January 2022","type":2,"subType":null,"childSubType":"","date":"1/31/2022","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xmpu-wny-jan-2022.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/mpu-wny-jan-2022.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eBiosimilar Preferred Product Established for Rituximab\u003c/li\u003e\n\u003cli\u003eGuidelines Established for Avalglucosidase alfa-ngpt (Nexviazyme)\u003c/li\u003e\n\u003cli\u003eBiosimilar Preferred Products Established for Pegfilgrastim\u003c/li\u003e\n\u003cli\u003eGuidelines Established for Eculizumab (Soliris)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Brentuximab Vedotin (Adcetris)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Parathyroid Hormone (Natpara)\u003c/li\u003e\n\u003cli\u003eAnd more...\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":36246,"versionId":16558,"title":"December 2021","type":2,"subType":null,"childSubType":"","date":"12/27/2021","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xmpu-wny-dec-2021.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/mpu-wny-dec-2021.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCriteria Revision for Obesity\u003c/li\u003e\n\u003cli\u003eInjectable Drug Added to Site of Care\u003c/li\u003e\n\u003cli\u003ePreferred Products Changed for Infliximab\u003c/li\u003e\n\u003cli\u003eCriteria Revision for Fecal Microbiota Transplantation\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":36198,"versionId":16558,"title":"November 2021","type":2,"subType":null,"childSubType":"","date":"11/29/2021","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xmpu-nov-2021-wny.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/mpu-nov-2021-wny.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eRevised Criteria for Wireless Capsule Endoscopy as a Diagnostic Technique in Disorders of the Small Bowel, Esophagus, and Colon\u003c/li\u003e\n\u003cli\u003eUPDATE: Oncology Imaging Guidelines\u003c/li\u003e\n\u003cli\u003eCriteria Revision for Ipilimumab (Yervoy)\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Disease\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u003c/p\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":36145,"versionId":16558,"title":"October 2021","type":2,"subType":null,"childSubType":"","date":"11/5/2021","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xmpu-oct-2021-wny-30-day.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/mpu-oct-2021-wny-30-day.pdf","baseUrl":null,"urlText":"Read","description":"\u003cp\u003eThis document includes a list and description of the following, including effective dates:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eNew medical policies\u003c/li\u003e\n\u003cli\u003eMedical policies without guidline changes\u003c/li\u003e\n\u003cli\u003eMedical policies with guideline changes\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":36066,"versionId":16558,"title":"October 2021","type":2,"subType":null,"childSubType":"","date":"10/25/2021","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/2xmpu-oct-2021-wny.png","url":"https://content.highmarkprc.com/Files/Region/hbcbswny/NewsletterNotices/MPU/mpu-oct-2021-wny.pdf","baseUrl":null,"urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCriteria Revised for Arthrex Bovine Collagen\u003c/li\u003e\n\u003cli\u003eCriteria Revision for Non-spinal Bone Growth Stimulation\u003c/li\u003e\n\u003cli\u003ePolicy Established for Amivantamab-vmjw (Rybrevant)\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":32341,"versionId":16558,"title":"September 2021","type":2,"subType":null,"childSubType":"","date":"9/27/2021","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-sept-2021-bs.png","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/mpu-sept-2021-hbs.pdf","baseUrl":null,"urlText":"Read","description":"\u003cp\u003e\u003cem\u003eBecause the Highmark Blue Cross Blue Shield of Western New York Provider Resource Center site was not yet live on September 27th\u0026nbsp;when this Medical Policy Update was distributed, we\u0027ve provided\u003cspan\u003e\u0026nbsp;\u003c/span\u003ethe Highmark Blue Shield\u003cspan\u003e\u0026nbsp;\u003c/span\u003eversion for reference.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eREMINDER: Laboratory Management Coverage Guidelines\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Fulvestrant (Faslodex)\u003c/li\u003e\n\u003cli\u003eBiosimilar Preferred Products Established for Bevacizumab, Rituximab, and Trastuzumab\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":32342,"versionId":16558,"title":"August 2021","type":2,"subType":null,"childSubType":"","date":"8/30/2021","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-hbs-august-2021.png","url":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/august-2021-mpu-hbs.pdf","baseUrl":null,"urlText":"Read","description":"\u003cp\u003e\u003cem\u003eBecause the Highmark Blue Cross Blue Shield of Western New York Provider Resource Center site was not yet live on August 30th when this Medical Policy Update was distributed, we\u0027ve provided the Highmark Blue Shield version for reference.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Irinotecan (Camptosar)\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Panitumumab (Vectibix)\u003c/li\u003e\n\u003cli\u003eRevised Criteria for Aqueous Shunts and Stents for Glaucoma\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Posterior Tibial Nerve Stimulation\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2}]